54gene Launches Diagnostic Arm 7RiverLabs to Boost Patient Health Outcomes

USA - English

• USA - Français
• Middle East - English

Launching in Nigeria, tech-enabled hubs set to scale precision diagnostics across Africa, providing patients with advanced, accessible and affordable diagnostic screening

LAGOS, Nigeria, Dec. 15, 2021 /PRNewswire/ -- 54gene, the health technology company advancing African genomics research for improved global health outcomes, has announced the launch of its diagnostic arm; 7RiverLabs. The diagnostic hubs fitted with state-of-the-art technology will offer healthcare providers and patients access to world-class, cost-effective, speedy, reliable and advanced molecular diagnostics. Sample collection centres with over 100 employees are already open in Lagos, Abuja, Kano and Port Harcourt, with more centres due to launch in 10 major  Nigerian cities in the coming months. Pan-African expansion for 7RiverLabs is also planned over the course of 2022. 

Since its launch in 2019, 54gene has driven genomics and molecular medicine throughout Africa. Formerly known as DiagnoseMe Africa, 7RiverLabs (named after the 7 major rivers on the continent), is designed to equalise precision medicine for African populations. Building  on that vision, 54gene has domesticated diagnostic technology; eliminating the need for samples to be sent abroad for analysis, at a considerable cost to the patient. Physicians will now be able to detect and prevent diseases earlier, thereby helping to improve patients' treatment outcomes and quality of health. 

As part of its mission to establish itself as a principal provider of diagnostic care driven by ultra-modern technology, 54gene has appointed its Chief Business Officer, Jude Uzonwanne as the diagnostic arm's interim-CEO. 

Through the use of state-of-the-art laboratories and marked workflow improvements, over 300 critical molecular tests can now be performed safely and securely - covering oncology, infectious diseases, genetic testing and sequencing, anatomic pathology, clinical chemistry, microbiology, haematology as well as communicable and non-communicable diseases. 

With some tests costing as little as a few thousand Naira - generally more affordable than the prevailing market rates - results, depending on the complexity, are provided in as little time as a few hours to a few days and are sent digitally to patients' physicians for follow-up. 

On the launch of 7RiverLabs, 54gene Founder and CEO Dr. Abasi Ene-Obong commented, "Launching 7RiverLabs is a manifestation of one of the goals 54gene set out to achieve two years ago - to improve diagnostic and treatment outcomes on the continent. With the range of tests 7RiverLabs offers, millions of Africans can begin to take greater control of their health. Our goal with this new diagnostics arm is to ensure that every African has access to our hubs offering advanced laboratory tests without having to pay an exorbitant out-of-pocket fee. Patients will receive speedy results that will guide their physicians in reducing late diagnoses leading to poor chances of survival, improve their treatment options and ultimately their quality of life." 

Jude Uzonwanne commented, "7RiverLabs is complementing Government and industry efforts to attain the Nigerian Ministry of Health's mandate towards improved care for the general population. Hundreds of molecular tests will be made available for millions of people at a fraction of the cost of transporting samples overseas thereby helping to increase early disease-detection and screening rates and save lives. This is groundbreaking news for Nigeria; and as we forge trusted partnerships with leading health insurers, hospitals and healthcare professionals, we anticipate that hundreds more jobs will be created in our expansion of services across Africa".

As of 2021, the addressable market for medical tests in Sub-Saharan Africa is currently worth US$10 billion. At present, the majority of molecular tests are sent outside of the continent; investment in this sector will see the market witness an expected average rate of more than 4% growth per annum. This will be directly linked to affordability, accurate diagnoses and lighting quick turnaround times - all of which 7RiverLabs is positioned to deliver not only in Nigeria, but across the continent. 

About 54gene
54gene is a health technology company centered on advancing the field of African genomics to unlock scientific discoveries as well as improve diagnostic and treatment outcomes within Africa and the global community. Founded in 2019, the company generates genetic insights from research cohorts in the world's most diverse populations to improve the development, availability and efficacy of therapeutics and diagnostics that will prove beneficial to all populations.

SOURCE 54gene